– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund

MOUNTAIN VIEW, Calif. , Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare

– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler , M.D., appointed as Chief Executive Officer and to Board of Directors – – Cash runway

MOUNTAIN VIEW, Calif. , Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, and Mary Beth Harler , M.D., Head, Research &

– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis clinical trial – – First dose cohort cleared in imvotamab systemic lupus erythematosus clinical trial –

MOUNTAIN VIEW, Calif. , May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in a fireside chat at the

- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif. , May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc.

MOUNTAIN VIEW, Calif. , May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference

Agreement focuses on immunology/inflammation, aligning with Sanofi’s ongoing commitment to advancing therapies for patients across multiple inflammatory diseases MOUNTAIN VIEW, Calif. , April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company

MOUNTAIN VIEW, Calif. , April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in a fireside chat at the Stifel